NEW YORK – Sophia Genetics said Wednesday that it is collaborating with Microsoft and Nvidia to commercialize a streamlined and scalable whole-genome sequencing (WGS) solution for clinical research, drug discovery, and patient care.
Under the collaboration, the Sophia DDM platform for WGS analysis will be powered by the Nvidia Parabricks data-processing software and hosted on the Microsoft Azure cloud. Sophia DDM is a software-as-a-service platform that analyzes genomic data alongside other clinical data, including diagnostic test results, imaging, pathology, and medical assessments, to inform drug discovery and development and treatment decisions.
The partners are designing the new WGS application to enable researchers and clinicians to make data-informed decisions within a day, Sophia said.
"By leveraging the powerful technologies and capabilities offered by Microsoft Azure and Nvidia, we are working to provide accurate, scalable, and rapid insights across multiple modalities, helping benefit our customers and, ultimately, patients, particularly those living with rare inherited disorders," Sophia Genetics Chief Technology Officer Abhimanyu Verma said in a statement.
"Whole-genome sequencing has the potential to enhance and accelerate treatment plans and drug development efforts," George Vacek, global head of genomics alliances at Nvidia, said in a statement. "Powered by Nvidia Parabricks, Sophia DDM can process whole genomes in minutes, unlocking new possibilities and helping drive meaningful impact for patients worldwide."
Sophia said that the partners aim to make the new solution available to customers before the end of this year.
Financial terms of the agreement were not disclosed.